Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-78.54M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.13 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -65.76% |
| Return on Assets (Trailing 12 Months) | -57.88% |
| Current Ratio (Most Recent Fiscal Quarter) | 8.07 |
| Quick Ratio (Most Recent Fiscal Quarter) | 8.07 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $8.40 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.25 |
| Earnings per Share (Most Recent Fiscal Year) | $-5.90 |
| Diluted Earnings per Share (Trailing 12 Months) | $-5.98 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 17.74M |
| Free Float | 17.03M |
| Market Capitalization | $168.67M |
| Average Volume (Last 20 Days) | 0.22M |
| Beta (Past 60 Months) | 2.84 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 64.64% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |